{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=58",
    "query": {
      "condition": "Multiple Myeloma",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 2319,
    "total_pages": 232,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Myeloma&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-03T15:23:34.802Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00036712",
      "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Oral Complications",
        "Ovarian Cancer",
        "Pain",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "management of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "pain therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 80,
      "start_date": "2002-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036712"
    },
    {
      "nct_id": "NCT00580034",
      "title": "Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Leukemia",
        "Myelodysplasia",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Campath Purged Non-myeloablative ASCT",
          "type": "DRUG"
        },
        {
          "name": "Donor Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "David Rizzieri, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 176,
      "start_date": "2003-02",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-06-03",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580034"
    },
    {
      "nct_id": "NCT04850599",
      "title": "Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Plasma Cell Myeloma",
        "Refractory Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Isatuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-06-14",
      "completion_date": "2029-02-21",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04850599"
    },
    {
      "nct_id": "NCT01518465",
      "title": "Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "dalteparin",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2012-01-09",
      "completion_date": "2017-10-31",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01518465"
    },
    {
      "nct_id": "NCT00729118",
      "title": "Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Plasma Cell Neoplasm"
      ],
      "interventions": [
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2008-09-26",
      "completion_date": "2020-05-04",
      "has_results": false,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00729118"
    },
    {
      "nct_id": "NCT02703779",
      "title": "Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte colony-stimulating factor (G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "Mozobil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Siddhartha Ganguly",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2016-03",
      "completion_date": "2020-04-08",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Westwood, Kansas",
      "locations": [
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02703779"
    },
    {
      "nct_id": "NCT04883242",
      "title": "Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Multiple Myeloma",
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Isatuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Skeletal Survey X-Ray",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2021-07-29",
      "completion_date": "2031-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883242"
    },
    {
      "nct_id": "NCT07772024",
      "title": "Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Myeloma Refractory",
        "Multiple Myeloma in Relapse"
      ],
      "interventions": [
        {
          "name": "InoPd",
          "type": "DRUG"
        },
        {
          "name": "Investigator's choice of SAT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CellCentric Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2026-08",
      "completion_date": "2031-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07772024"
    },
    {
      "nct_id": "NCT00049296",
      "title": "Thalidomide and Docetaxel in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "thalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2002-07",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2010-06-11",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00049296"
    },
    {
      "nct_id": "NCT03424603",
      "title": "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Lymphoma",
        "Non Hodgkin Lymphoma",
        "Multiple Myeloma",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Diffuse Large B Cell Lymphoma",
        "Indolent Lymphoma",
        "B Cells--Tumors"
      ],
      "interventions": [
        {
          "name": "STRO-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sutro Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2018-02-22",
      "completion_date": "2024-03-15",
      "has_results": false,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-11-03T15:23:34.802Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03424603"
    }
  ]
}